Immunogenicity and Protective Efficacy of a Single Intranasal Dose Vectored Vaccine Based on Sendai Virus (Moscow Strain) against SARS-CoV-2 Variant of Concern

Immunogenicity and Protective Efficacy of a Single Intranasal Dose Vectored Vaccine Based on Sendai Virus (Moscow Strain) against SARS-CoV-2 Variant of Concern

The mouse paramyxovirus Sendai, which is capable of limited replication in human bronchial epithelial cells without causing disease, is well suited for the development of vector-based intranasal vaccines against respiratory infections, including SARS-CoV-2. Using the Moscow strain of the Sendai viru...

Full description

Bibliographic Details
Main Authors: Galina V. Kochneva, Gleb A. Kudrov, Sergei S. Zainutdinov, Irina S. Shulgina, Andrei V. Shipovalov, Anna V. Zaykovskaya, Mariya B. Borgoyakova, Ekaterina V. Starostina, Sergei A. Bodnev, Galina F. Sivolobova, Antonina A. Grazhdantseva, Daria I. Ivkina, Alexey M. Zadorozhny, Larisa I. Karpenko, Oleg V. P’yankov
Format: Article
Language:English
Published: MDPI AG 2024-07-01
Series:Vaccines
Subjects:
Sendai virus
Moscow strain
recombinant variant
vectored vaccine
SARS-CoV-2 variant of concern
S protein
Online Access:https://www.mdpi.com/2076-393X/12/7/783

Internet

https://www.mdpi.com/2076-393X/12/7/783

Similar Items